Company Website

Contact information

Rebecca Bean, MSN, RN, OCN
rbean@karyopharm.com 
914-260-8741

 

Virtual Exhibit Hall Home

Karyopharm Therapeutics is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets in cancer. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with certain blood cancers.

Learn About Our Mechanism of Action

Additional Information:

Prescribing Information

HCP Resources

Getting Patients Started